mGluRs: A target for pharmacotherapy in Parkinson disease

Jennifer A Feeley Kearney, Roger L. Albin*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Metabotropic glutamate receptors (mGluRs) are G-protein-coupled excitatory amino acid (glutamate) receptors and are abundantly expressed in basal ganglia nuclei. We used behavioral, regional glucose uptake metabolic mapping, and FOS protein expression to examine the effects of stimulating striatal and subthalamic mGluRs in rats. Stimulation of striatal Group I mGluRs produced behavioral effects mediated by polysynaptic activation of subthalamic neurons. Stimulation of subthalamic Group II mGluRs produced similar effects. Excessive activity of subthalamic neurons is a key feature of parkinsonism. mGluR Group I or Group II antagonists may prove to be useful for symptomatic treatment of parkinsonism. Stimulation of Group III mGluRs produced behavioral effects in only 6-hydroxydopamine-lesioned animals. Regional glucose uptake metabolic mapping and FOS expression studies suggested that striatal dopamine denervation produced increased sensitivity of Group III mGluRs. Agents active at Group III mGluRs may also be useful for treatment of parkinsonism.

Original languageEnglish (US)
Pages (from-to)30-36
Number of pages7
JournalExperimental Neurology
Issue numberSUPPL. 1
StatePublished - Nov 15 2003

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience


Dive into the research topics of 'mGluRs: A target for pharmacotherapy in Parkinson disease'. Together they form a unique fingerprint.

Cite this